Jefferies Financial Group Analysts Give Pacira Biosciences (NASDAQ:PCRX) a $60.00 Price Target

Jefferies Financial Group set a $60.00 price target on Pacira Biosciences (NASDAQ:PCRX) in a research note issued to investors on Tuesday, TipRanks reports. The firm currently has a buy rating on the stock. Jefferies Financial Group also issued estimates for Pacira Biosciences’ Q3 2019 earnings at $0.21 EPS, Q4 2019 earnings at $0.39 EPS, FY2019 earnings at $0.83 EPS and FY2020 earnings at $1.75 EPS.

Other equities research analysts have also issued research reports about the stock. Wedbush set a $85.00 price objective on shares of Pacira Biosciences and gave the company a buy rating in a research note on Friday, June 28th. Barclays began coverage on shares of Pacira Biosciences in a research note on Tuesday, June 11th. They issued an overweight rating and a $52.00 price objective for the company. BMO Capital Markets decreased their price objective on shares of Pacira Biosciences from $46.00 to $43.00 and set a market perform rating for the company in a research note on Friday, August 9th. BidaskClub lowered shares of Pacira Biosciences from a hold rating to a sell rating in a research note on Thursday, October 3rd. Finally, Zacks Investment Research upgraded shares of Pacira Biosciences from a sell rating to a hold rating and set a $47.00 price objective for the company in a research note on Friday, August 2nd. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $55.00.

PCRX opened at $37.69 on Tuesday. The company has a debt-to-equity ratio of 0.99, a current ratio of 4.75 and a quick ratio of 4.12. The firm has a market capitalization of $1.53 billion, a PE ratio of 129.97, a P/E/G ratio of 1.74 and a beta of 1.11. Pacira Biosciences has a fifty-two week low of $34.64 and a fifty-two week high of $55.00. The company’s 50-day moving average is $37.54 and its 200 day moving average is $40.87.



Pacira Biosciences (NASDAQ:PCRX) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.41 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.27. The firm had revenue of $102.60 million during the quarter, compared to analyst estimates of $99.92 million. Pacira Biosciences had a net margin of 2.04% and a return on equity of 8.62%. The company’s revenue for the quarter was up 22.0% on a year-over-year basis. During the same quarter last year, the business posted $0.24 EPS. As a group, analysts expect that Pacira Biosciences will post 0.64 EPS for the current year.

In other news, CEO David M. Stack sold 12,849 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $39.15, for a total transaction of $503,038.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Kristen Marie Williams sold 6,252 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $39.49, for a total transaction of $246,891.48. The disclosure for this sale can be found here. 5.80% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the company. HM Payson & Co. bought a new position in shares of Pacira Biosciences during the 2nd quarter valued at approximately $39,000. C M Bidwell & Associates Ltd. bought a new position in shares of Pacira Biosciences during the 2nd quarter valued at approximately $44,000. Tower Research Capital LLC TRC grew its position in shares of Pacira Biosciences by 414.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,436 shares of the company’s stock valued at $63,000 after acquiring an additional 1,157 shares during the period. Steward Partners Investment Advisory LLC bought a new position in shares of Pacira Biosciences during the 2nd quarter valued at approximately $71,000. Finally, Amundi Pioneer Asset Management Inc. bought a new position in shares of Pacira Biosciences during the 1st quarter valued at approximately $65,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

Pacira Biosciences Company Profile

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Featured Story: Put Option Volume

Analyst Recommendations for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.